Tech Center 1600 • Art Units: 1611 1612 1628
This examiner grants 37% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18007433 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | Non-Final OA | GENZYME CORPORATION |
| 17824552 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Non-Final OA | GENZYME CORPORATION |
| 18028618 | USE OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Non-Final OA | LG CHEM, LTD. |
| 19253364 | ROCK INHIBITORS AND USES THEREOF | Non-Final OA | Alcon Inc. |
| 17999299 | GRANULES FOR 3D PRINTING TECHNOLOGY | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17420252 | PI4-Kinase Inhibitors with Anti-Cancer Activity | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 19187713 | TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | Non-Final OA | Io Therapeutics, Inc. |
| 18415139 | METHODS FOR TREATING PAIN | Non-Final OA | Xenon Pharmaceuticals Inc. |
| 18245970 | COMBINATION COMPOSITIONS HAVING ANTI-VIRAL ACTIVITIES AND USES THEREOF | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18361073 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | Non-Final OA | ENZO BIOCHEM, INC. |
| 17912802 | USE OF A COMPOUND OR COMPOSITION COMPRISING AN INHIBITOR OF NLRP1 INFLAMMASOME ACTIVATION FOR THE TREATMENT OF HUMAN AIRWAY INFLAMMATION | Non-Final OA | Agency for Science, Technology and Research |
| 18452885 | Use of Histamine Antagonists and Glucocorticoid for Treating and Preventing Neurodegenerative Diseases | Non-Final OA | City University of Hong Kong |
| 17772856 | THERAPEUTIC METHODS USING VADADUSTAT | Final Rejection | Mitsubishi Tanabe Pharma Corporation |
| 18265595 | SMARCA DEGRADERS AND USES THEREOF | Non-Final OA | Kymera Therapeutics, Inc. |
| 17343965 | ORGANIC COMPOUNDS | Non-Final OA | Rutgers, The State University of New Jersey |
| 18251670 | CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 18329957 | METHODS OF TREATING DISEASES AND DISORDERS ASSOCIATED WITH CALCIUM ION SIGNALING | Non-Final OA | Temple University-Of the Commonwealth System of Higher Education |
| 18263211 | ANTIPARASITIC COMPOUNDS | Non-Final OA | Intervet Inc. |
| 17737626 | CHANGING COGNITIVE FUNCTION WITH FENFLURAMINE | Non-Final OA | ZOGENIX INTERNATIONAL LIMITED |
| 18560968 | NEW FORMULATION FOR INJECTION COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | Non-Final OA | DAEWOONG PHARMACEUTICAL CO., LTD. |
| 17417557 | R-KETAMINE AND DERIVATIVE THEREOF AS PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEURODEVELOPMENTAL DISORDER | Non-Final OA | National University Corporation Chiba University |
| 18031899 | METHODS FOR TREATING CHOLESTATIC PRURITUS | Non-Final OA | GlaxoSmithKline Intellectual Property (No.2) Limited |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | Non-Final OA | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT |
| 17925166 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | Non-Final OA | NOVARTIS PHARMA AG |
| 17789399 | D-SERINE TRANSPORT MODIFIER AND SCREENING METHOD THEREOF, AND SCREENING METHOD OF D-SERINE TRANSPORTER PROTEIN | Non-Final OA | National Institutes of Biomedical Innovation, Health and Nutrition |
| 18137949 | METHOD OF TREATING ACUTE MIGRAINE WITH CGRP-ACTIVE COMPOUND | Non-Final OA | Merck Sharp & Dohme Corp. |
| 18191440 | METHOD FOR TREATING CEREBRAL APOPLEXY AND HYPERBILIRUBINEMIA BY COMPOUND FOR INHIBITING COMBINATION OF BILIRUBIN AND TRPM2 CHANNEL | Final Rejection | SHANGHAI SIXTH PEOPLE'S HOSPITAL |
| 18040569 | SENSORY STIMULATING PSYCHOTROPIC DRUG | Non-Final OA | SCENT SCIENCE INTERNATIONAL INC. |
| 18102268 | EXTENDED RELEASE 5-HT RECEPTOR AGONISTS FOR NEUROLOGICAL CONDITIONS | Non-Final OA | Diamond Therapeutics Inc. |
| 17927780 | MONO- AND BIS-NITROSYLATED ALKYL POLYOLS FOR THERAPEUTIC USE | Non-Final OA | ATTGENO AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy